Bonesupport Holding AB (publ) (BONEX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

basically driven by continued adoption and a clear pickup in trauma. If you look at some of the highlights in the quarter, at the AAOS meeting, the American Academy of Orthopedic Surgeons, that meeting was held earlier this year, and bone support hosted a well-attended satellite symposium focused on bone infection, featuring a European professor with deep expertise in trauma-induced bone infections. In addition, there were several trauma patient cases presentations from prominent U.S. trauma surgeons. Their real-world cases showed excellent results, mirroring the positive patient outcome seen in large-scale published clinical studies from, among others, Manchester University Hospital. We're seeing a strong interest among trauma surgeons, especially those dealing with severe injuries from, in example, traffic accidents where infection risk is high. Many of these surgeons have not previously used any local antibiotics, mainly due to the lack of FDA approved options. Saruman G is now filling that gap and expanding their infection prevention toolkit for a large part of the market. As mentioned earlier, Cerament V market authorization request was submitted to the FDA at the end of the quarter. This is an important step in providing surgeons with a broader range of local antibiotic solution, especially in the face of rising antimicrobial resistance and the awareness of proper antibiotic stewardship. The submission is based on a very comprehensive data package, including Cerament's mechanism of action, bone remodeling data, biocompatibility, and elution data, supplemented with specific Cerament V patient data. The submission is tailored to meet the very strict and unique special controls that FDA has defined for the product category antibiotic elutin bone void fillers, whic...